过去一年中添加的文章，按日期排序
[HTML][HTML] … plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 …
YY Evan, C Ferrario, MD Linch, M Stoeckle… - European Urology …, 2024 - Elsevier
13 天前 - … Abiraterone acetate (abiraterone) plus prednisone is approved for the treatment of
metastatic castration-resistant prostate cancer (… pembrolizumab plus abiraterone in mCRPC. …
metastatic castration-resistant prostate cancer (… pembrolizumab plus abiraterone in mCRPC. …
[HTML][HTML] Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
T Kulasegaran, N Oliveira - Current Treatment Options in Oncology, 2024 - Springer
14 天前 - … Chemotherapy treatments such as docetaxel remain the … status and in those with
no previous progression on docetaxel. … the use of abiraterone plus olaparib vs abiraterone plus …
no previous progression on docetaxel. … the use of abiraterone plus olaparib vs abiraterone plus …
Phase 3 trial of [177Lu] Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)
38 天前 - … Randomization was 1:1 to open-label 177 Lu-PSMA-617 (7.4 GBq every 6 weeks
for 6 cycles) or ARPI change (abiraterone or enzalutamide). Patients randomized to ARPI …
for 6 cycles) or ARPI change (abiraterone or enzalutamide). Patients randomized to ARPI …
… ) versus olaparib plus abiraterone and prednisone/prednisolone (OLAP+ AAP) for first-line (1L) therapy in patients with metastatic castration-resistant prostate cancer …
40 天前 - … including prior taxane chemotherapy in castration sensitive prostate cancer (CSPC),
visceral metastasis, bone only metastasis, Eastern Cooperative Oncology Group score, …
visceral metastasis, bone only metastasis, Eastern Cooperative Oncology Group score, …
Health-related quality of life and pain in a phase 3 study of [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer …
40 天前 - … or had received prior systemic radiotherapy, immunotherapy or chemotherapy. Patients
… /6 weeks; 6 cycles) or ARPI change (abiraterone/enzalutamide). Patients with confirmed …
… /6 weeks; 6 cycles) or ARPI change (abiraterone/enzalutamide). Patients with confirmed …
… hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after NHA and taxane-based chemotherapy: Phase 3 MK-5684 …
EY Yu, Y Song, CH Poehlein, C Schloss… - 2024 - ascopubs.org
40 天前 - … Approximately 1200 patients (300 with and 900 without AR-LBD mutations) will be
… (if prior abiraterone) or abiraterone acetate 1000 mg PO QD (+ prednisone 5 mg BID; if prior …
… (if prior abiraterone) or abiraterone acetate 1000 mg PO QD (+ prednisone 5 mg BID; if prior …
A phase 1b study of PSCA CAR T cells plus or minus radiation for the treatment of patients with PSCA+ metastatic castration-resistant prostate cancer.
PD Zang, S Blanchard, H Martirosyan, L Adkins… - 2024 - ascopubs.org
40 天前 - … disease, at least one area of metastasis amenable for radiation (for the MDRT cohort),
… prior progression on abiraterone or enzalutamide or both; prior taxane chemotherapy is …
… prior progression on abiraterone or enzalutamide or both; prior taxane chemotherapy is …
… AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair …
40 天前 - … plus physician’s choice of NHA (abiraterone, darolutamide, or enzalutamide) compared
with … prior therapy with PARPi, prior chemotherapy or NHAs in the mCSPC setting (prior …
with … prior therapy with PARPi, prior chemotherapy or NHAs in the mCSPC setting (prior …
Interim analysis of clinical data and reasons for initiating relugolix on a cohort of US patients: The OPTYX study.
DE Spratt, RR McKay, A Ross, BH Lowentritt… - 2024 - ascopubs.org
41 天前 - … antagonist indicated for advanced prostate cancer treatment. … 1,000 patients with
prostate cancer starting relugolix therapy. … had received prior radiotherapy and 20.0% had prior …
prostate cancer starting relugolix therapy. … had received prior radiotherapy and 20.0% had prior …
Utidelone for heavily pretreated metastatic castration-resistant prostate cancer after failing docetaxel treatment: An open-label, single-arm, phase II trial.
M Chen, X An, C Xue, H Li, W Yang, R Huang, J Peng… - 2024 - ascopubs.org
41 天前 - … : The appropriate chemotherapy for metastatic castration-resistant prostate cancer
(… , men with progressive mCRPC after docetaxel and abiraterone, and/or enzalutamide, and/…
(… , men with progressive mCRPC after docetaxel and abiraterone, and/or enzalutamide, and/…